Content continues after advertisement

Wound Infection in a Labrador Retriever

J. Scott Weese, DVM, DVSc, Diplomate ACVIM, University of Guelph

Pharmacology & Medications

|October 2009|Peer Reviewed

Sign in to Print/View PDF

Archie, a 4-year-old Labrador retriever, is presented for evaluation of a wound infection.

History. Five days previously, Archie sustained a shallow laceration over the ventrolateral aspect of the abdomen while playing unobserved outside. His owner has been cleaning the wound with antibacterial soap and applying a topical antimicrobial (polymyxin B). Archie is the only pet in the household and his vaccinations and parasite prevention are up to date.
 
Physical Examination. Archie is bright, alert, responsive, and afebrile. A 2-cm wound is present over the abdomen, and a small amount of purulent discharge is present. Warmth and erythema extend approximately 5 to 10 cm from the site of the wound, and palpation of the area elicits pain. The wound is cleaned and a swab of the discharge is taken for culture. Amoxicillin/clavulanic acid is prescribed, and the owner is advised to clean the wound daily with dilute chlorhexidine solution.

Laboratory Results. Two days later, the laboratory results shown in the Table are received.

Laboratory Results
Organism: Staphylococcus aureus 
Antimicrobial   -  Sensitivity   
Penicillin  -  Resistant   
Cephalothin  -  Resistant   
Cefoxitin  -  Resistant   
Oxacillin  -  Resistant   
Cefotaxime  -  Resistant   
Tetracycline -   Resistant   
Enrofloxacin  -  Sensitive   
Gentamicin  -  Resistant   
Chloramphenicol  -   Resistant   
Trimethoprim–sulfamethoxazole  -  Sensitive   
Amoxicillin/clavulanic acid  -  Resistant   
Erythromycin  -  Resistant   
Clindamycin  -  Sensitive   

ASK YOURSELF...
What is the best antimicrobial choice in this case?
A.     Enrofloxacin
B.     Clindamycin
C.     Trimethoprim–sulfamethoxazole
D.     Imipenem
E.     Vancomycin

Correct Answer:
C. Trimethoprim–sulfamethoxazole

On the basis of oxacillin resistance, methicillin-resistant Staphylococcus aureus (MRSA) has been isolated from this dog. Methicillin susceptibility was not tested because methicillin is poorly stable in vitro; therefore, oxacillin and/or cefoxitin are used. A 2-week course of trimethoprim–sulfamethoxazole (30 mg/kg PO Q 12 H) is prescribed, and a follow-up appointment is scheduled to determine whether treatment will need to be continued. Household infection-control practices are discussed to reduce the risk of zoonotic transmission.

Antibiotic Selection. MRSA is an emerging problem in veterinary medicine and selecting an appropriate antimicrobial can sometimes be complicated.

Fluoroquinolones
The use of fluoroquinolones for treatment is considered suboptimal in humans due to the potential for resistance developing during treatment and the poor correlation between in vitro susceptibility and clinical response.1 The same principle most likely applies to animals; therefore, other options are probably better in this case given the apparently invasive nature of this infection.

Clindamycin
Clindamycin susceptibility is reported, but this isolate could be resistant. A phenomenon of inducible clindamycin resistance can be present in S aureus2 whereby isolates appear susceptible with routine testing but are truly resistant. In a recent study, over 50% of erythromycin-resistant MRSA from dogs and cats was inducibly resistant to clindamycin.3

A D-test (Figure 1) is used to identify resistance to clindamycin with exposure to erythromycin. With a positive test, as shown in the figure, there is a blunting of the zone of inhibition around the clindamycin disk adjacent to the erythromycin disk, creating a “D” shape. However, this test is not readily available in most veterinary laboratories. Because this isolate is erythromycin-resistant, it should be considered to be clindamycin-resistant until proven otherwise.


 
Imipenem
Imipenem susceptibility data are not available, but the isolate would be resistant because MRSA is resistant to all beta-lactams (eg, penicillins, cephalosporins, carbapenems).

Vancomycin
Another option, vancomycin, is commonly used in human medicine; however, principles of prudent antimicrobial use4 dictate that drugs important for serious infections in humans should be used sparingly in veterinary medicine. There is some controversy as to whether vancomycin should be used in animals at all, but most experts would agree that it should be reserved for cases where there are no other reasonable options.5 In addition, vancomycin must be administered intravenously, which is not desirable in a case such as this.

Trimethoprim–Sulfamethoxazole
Trimethoprim–sulfamethoxazole (TMS) is left as the best option. Although TMS is an “old” drug, it can be highly effective and is sometimes used to treat MRSA infections in people. It is typically used sparingly in dogs because of concerns about adverse effects, including keratoconjunctivitis sicca (“dry eye”), arthropathy, hepatic necrosis, and bone marrow suppression.

However, TMS is cost-effective and can be administered orally, and Labrador retrievers are not a breed at increased risk for keratoconjunctivits sicca. In Archie’s case, invasive infection may be present (and there are few other options), so TMS is a reasonable choice.

Follow-Up.
A Schirmer’s tear test should be performed before initiating treatment, periodically thereafter (ie, every 10–14 days) if treatment is prolonged, and for a few weeks after cessation of therapy. The client should also be advised to watch for mucoid ocular discharge and to return for evaluation of the wound in a week or sooner if any signs of deterioration are noted.

Outcome. Archie recovered uneventfully. After 2 weeks of appropriate treatment, the infection was eliminated and the wound healed normally.

Clinician's Brief

WOUND INFECTION IN A LABRADOR RETRIEVER • J. Scott Weese

References
1. Strategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention. Gorwitz RJ, Jernigan DB, Powers JH, et al. cdc.gov/ncidod/dhqp/ar_mrsa_ca.html
2. Clindamycin-resistance in methicillin-resistant Staphylococcus aureus isolated from animals. Rich M, Deighton L, Roberts L. Vet Microbiol 111:237-240, 2005.
3. Prevalence of inducible clindamycin-resistant Staphylococcus aureus isolates from dogs and cats. Faires M, Weese JS. Proc ASM Conference on Antimicrobial Resistance in Zoonotic and Foodborne Pathogens, 2008; Copenhagen, Denmark.
4. Antimicrobial drug use in veterinary medicine. Morley P, Apley M, Besser T, et al. J Vet Intern Med 19:617-629, 2005.
5. Issues regarding the use of vancomycin in companion animals. Weese JS. JAVMA 233: 565-567, 2008.

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy